Company Profile of Alicorn Pharmaceutical Co., Ltd

Brief Introduction Alicorn pharmaceutical Co.,Ltd is a national high-tech enterprise engaged in the R&D and manufacturing of innovative drugs、modified new drugs、generic drugs and pharmaceutical intermediates.It has been been equipped with two R&D centers respectively in Nanjing Jiangsu province and Jiaxing Zhejiang province of China.Our own wholly owned manufacturing site is located in Anqing high-tech industry zone of Anhui province,the manufacturing site is used to produce the APIs and final drugs covering an area of 72mu. Our business scope R&D and registration Research and development of generic drugs Research and development of innovative drugs Conformance evaluation of generic drugs Process optimization and changes of APIs and final drugs Patent strategic consulting Application and registration consulting Technical service and consulting Customization and production New molecular compound customized synthesis Pharmaceutical intermediates customized manufacturing APIs customized manufacturing APIs and final drugs joint development APIs contract manufacturing Final drugs contract manufacturing Nanjing R&D center It covers an area of 1800 square meters,mainly dedicated in the process research and optimization of APIs 、pharmaceutical intermediates、solid & liquid drugs and quality & stability research. Jiaxing R&D center It covers an area of over 3500 square meters,mainly participated in the customization and synthesis of new molecular compound. Anqing Technical center ( under construction) The lab has an area of 1200 square meters,mainly used for the process optimization、finalize、scale-up and costing control of APIs and pharmaceutical intermediates. Anqing manufacturing base Land area: 48000 square meters Gross floor area: 40000 square meters The APIs & intermediates manufacturing site covers an area of 15000 square meters, the 500-5000L reactors can be available for specific reactions including high temperature、high pressure、cryogenic and hydrogenation reactions. The final drugs manufacturing site has an area of 11000 square meters for the production of oral solid drugs and external drugs.